---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037923"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:23:59.380042+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%

## Summary
- Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).
- Q2 net loss $741k; YTD net income $516k; adjusted YTD EPS $0.18.
- Ifetroban Phase II DMD trial showed 5.4% improvement in cardiac function; FDA submission completed.
- Vibativ 4-vial starter pak now available via Vizient, covering >65% of U.S. acute care providers.
- Cash and equivalents $16M; total assets $68M; shareholders' equity $28M.

## SEC filing metadata
- accession: 0001628280-25-037923
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828025037923/0001628280-25-037923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828025037923/cpix-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037923
- JSON: https://secwatch.observer/filing/0001628280-25-037923.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.